Encequidar mesylate/Topotecan (Athenex)

N/A

Report date: 2026/01/09 20:00:57

Base Information

Drug NameEncequidar mesylate/Topotecan (Athenex)
Drug Alias NameTopotecan/encequidar (Athenex)Topotecan+HM-30181A (Athenex)Topotecan+Encequidar mesylate (Athenex)Encequidar mesylate+Topotecan (Athenex)Encequidar/topotecan (Athenex) +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP-glycoprotein 1 inhibitorsDNA topoisomerase I inhibitors
TargetsP-glycoprotein 1DNA topoisomerase I
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsYes Encequidar mesylateTopotecan Hydrochloride
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAthenex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAthenex Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A